Earnings summaries and quarterly performance for Aclarion.
Executive leadership at Aclarion.
Board of directors at Aclarion.
Research analysts covering Aclarion.
Recent press releases and 8-K filings for ACON.
Aclarion Closes $10.4 Million Common Stock Offering and Extends Cash Runway
ACON
New Projects/Investments
Guidance Update
- Aclarion, Inc. announced the closing of a $10.4 million common-stock-only financing at $5.18 per share.
- This transaction significantly strengthens the company's balance sheet and extends its cash runway into 2028 based on current operating plans.
- As of January 12, 2026, Aclarion has $21.6 million in cash and zero debt.
Jan 13, 2026, 2:00 PM
Aclarion, Inc. announces $10.36 million registered direct offering
ACON
- Aclarion, Inc. entered into a Securities Purchase Agreement on January 8, 2026, for a registered direct offering.
- The offering includes the sale of 200,000 shares of common stock at $5.18 per share and pre-funded warrants to purchase up to 1,800,000 shares of common stock.
- The aggregate gross proceeds from the offering are expected to be approximately $10.36 million, before deducting a 6.0% cash fee for the placement agent, Dawson James Securities, Inc., and other estimated offering expenses.
- The net proceeds are intended to fund market development, clinical evidence (The Clarity Trial), product development and quality, general and administration support, and other general corporate purposes.
- The offering is expected to close on or about January 9, 2026.
Jan 9, 2026, 2:03 PM
Aclarion discusses business strategy and financial position at investor conference
ACON
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Aclarion (ACON) is addressing chronic low back pain with its Nosyscan technology, a non-invasive diagnostic that uses MR spectroscopy and AI to identify painful discs, targeting a $40 billion US market.
- The company holds a robust intellectual property portfolio, including 24 issued US patents and 17 international patents related to its technology.
- Aclarion is conducting the CLARITY trial, a national randomized controlled trial with 300 patients, to generate evidence for insurance reimbursement in the US; notably, three of the top four payers in London are already reimbursing for Nosyscan.
- Financially, Aclarion reports zero debt, is Nasdaq compliant, and possesses sufficient cash on hand to fund operations through 2027 with an estimated cash burn rate of $2 million.
Oct 20, 2025, 7:00 PM
ACON Presents Financials, Product, and Growth Strategy at Investor Conference
ACON
New Projects/Investments
Management Change
Guidance Update
- ACON reports zero debt, no preferred shares, and is NASDAQ compliant, with cash on hand providing runway through Q1 of fiscal 2027.
- The company's product, NOCISCAN, is a non-invasive diagnostic using MR spectroscopy and AI-driven algorithms to identify the source of chronic low back pain, targeting a $10 billion U.S. lumbar fusion market and a broader $40 billion market for invasive procedures.
- Key growth catalysts include the ongoing Clarity trial, a national randomized controlled trial, private payer approvals in London driving scan volume growth, and leveraging AMA codes in the U.S. with key opinion leader (KOL) advocacy.
- ACON recently hired Greg Gould as CFO and highlights its experienced management team, including the CEO's prior experience with HeartFlow's successful SaaS model.
Oct 20, 2025, 7:00 PM
Aclarion, Inc. announces $2.5 million registered direct offering
ACON
New Projects/Investments
- Aclarion, Inc. entered into a Securities Purchase Agreement on October 13, 2025, for a registered direct offering expected to close on or about October 14, 2025.
- The offering includes the sale of 64,000 shares of common stock at $8.36 per share and pre-funded warrants to purchase up to 236,000 shares of common stock with an exercise price of $0.00001.
- The aggregate gross proceeds from the offering are expected to be approximately $2.5 million, before deducting placement agent fees of 7.0% and other estimated offering expenses.
- The net proceeds will be used to fund market development and clinical evidence, The Clarity Trial, product development and quality, general and administration support, and other general corporate purposes.
- The company has agreed to a 60-day restriction on issuing additional common stock or equivalents after the closing date, subject to certain conditions.
Oct 14, 2025, 10:05 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more